MY210469A - Pcsk9 inhibitors and methods of use thereof - Google Patents

Pcsk9 inhibitors and methods of use thereof

Info

Publication number
MY210469A
MY210469A MYPI2021003994A MYPI2021003994A MY210469A MY 210469 A MY210469 A MY 210469A MY PI2021003994 A MYPI2021003994 A MY PI2021003994A MY PI2021003994 A MYPI2021003994 A MY PI2021003994A MY 210469 A MY210469 A MY 210469A
Authority
MY
Malaysia
Prior art keywords
methods
pcsk9 inhibitors
pcsk9
inhibitors
bind
Prior art date
Application number
MYPI2021003994A
Inventor
Doug Daniels
Virendar Kaushik
Brian K Hubbard
Michael H Serrano-Wu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY210469A publication Critical patent/MY210469A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.
MYPI2021003994A 2019-01-18 2020-01-16 Pcsk9 inhibitors and methods of use thereof MY210469A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962794239P 2019-01-18 2019-01-18
PCT/US2020/013882 WO2020150474A1 (en) 2019-01-18 2020-01-16 Pcsk9 inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MY210469A true MY210469A (en) 2025-09-24

Family

ID=71608564

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021003994A MY210469A (en) 2019-01-18 2020-01-16 Pcsk9 inhibitors and methods of use thereof

Country Status (15)

Country Link
US (2) US11603523B2 (en)
EP (1) EP3911640A4 (en)
JP (2) JP2022518016A (en)
KR (2) KR20210116549A (en)
CN (1) CN113412258A (en)
AU (3) AU2020209216A1 (en)
BR (1) BR112021013924A2 (en)
CA (1) CA3125767A1 (en)
EA (1) EA202191890A1 (en)
IL (1) IL284661A (en)
MA (1) MA54758A (en)
MX (2) MX2021008661A (en)
MY (1) MY210469A (en)
SG (1) SG11202107615TA (en)
WO (1) WO2020150474A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202107614PA (en) * 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
AU2020209216A1 (en) * 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN113248501B (en) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 CLY series compounds, preparation method thereof and application thereof in preparing medicines
CN113735846A (en) * 2021-10-11 2021-12-03 河北师范大学 Benzothiazole derivative and medical application thereof
WO2023084449A1 (en) * 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US20240217951A1 (en) 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240228469A1 (en) 2022-09-23 2024-07-11 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN121850939A (en) * 2022-10-14 2026-04-14 上海翰森生物医药科技有限公司 Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof
AU2024290864A1 (en) * 2023-07-04 2026-02-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof
CN121443616A (en) 2023-07-27 2026-01-30 上海拓界生物医药科技有限公司 Diaminocyclopentyl-substituted heteroaryl derivatives, their uses and preparation methods
TW202547505A (en) 2024-02-05 2025-12-16 瑞典商阿斯特捷利康公司 Pharmaceutical compositions comprising azd0780
WO2025168652A1 (en) 2024-02-05 2025-08-14 Astrazeneca Ab Azd-0780 in combination with a statin for use in lowering ldl-c levels and treating cardiovacular diseases
WO2025183455A1 (en) * 2024-02-29 2025-09-04 재단법인 대구경북첨단의료산업진흥재단 Benzoxazole derivatives as pcsk9 inhibitor
TW202539678A (en) * 2024-03-20 2025-10-16 瑞典商阿斯特捷利康公司 Pcsk9 inhibitors and methods of use thereof
WO2025214500A1 (en) * 2024-04-12 2025-10-16 上海翰森生物医药科技有限公司 Free base crystal form of nitrogen-containing heterocyclic derivative, acid salt and crystal form thereof, preparation method therefor, and use thereof
WO2025238159A1 (en) 2024-05-16 2025-11-20 Astrazeneca Ab Combination therapy comprising azd0780 and ezetimibe
WO2026021380A1 (en) * 2024-07-22 2026-01-29 深圳信立泰药业股份有限公司 Pcsk9 and hmg-coa dual-target compound and use thereof
WO2026026878A1 (en) * 2024-07-30 2026-02-05 成都施贝康生物医药科技有限公司 Heterocyclic derivative inhibitor, and preparation thereof and use thereof

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
DE69531543T2 (en) 1994-06-17 2004-06-24 F. Hoffmann-La Roche Ag N, N'-BIS (CHINOLIN-4-YL) DIAMINE DERIVATIVES, THEIR PRODUCTION AND THE USE THEREOF AS AN ANTIMALARIA AGENT
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
NZ325248A (en) 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
SE9603285D0 (en) 1996-09-10 1996-09-10 Astra Ab New compounds
US5874438A (en) 1996-10-11 1999-02-23 Bayer Aktiengesellschaft 2,2'-bridged bis-2,4-diaminoquinazolines
DK0999825T3 (en) 1997-07-29 2004-02-09 Alcon Lab Inc Ophthalmic compositions containing galactomannan polymers and borates
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20040138284A1 (en) 2000-02-11 2004-07-15 Matthias Wiesner Indol-3-yl derivatives
GB0014022D0 (en) 2000-06-08 2000-08-02 Novartis Ag Organic compounds
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
CA2461202C (en) 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2003209321A1 (en) 2002-01-18 2003-07-30 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
US7312214B2 (en) 2002-05-10 2007-12-25 Bristol-Myers Squibb Company 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
US20040087590A1 (en) 2002-08-23 2004-05-06 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
AU2003299790A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20050197350A1 (en) 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
KR20050114283A (en) 2003-04-22 2005-12-05 아바니르 파마슈티컬스 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MXJL06000069A (en) * 2004-06-09 2007-04-10 Avanir Pharmaceuticals Heterocyclic derivatives for treatment of hyperlipidemia and related diseases.
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US20080090863A1 (en) 2004-09-30 2008-04-17 Taisho Pharmaceutical Co., Ltd. Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
JP2008531596A (en) 2005-02-25 2008-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Benzisothiazole useful for treating or preventing HCV infection
CA2603830A1 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
JP5118029B2 (en) 2005-06-14 2013-01-16 タイゲン バイオテクノロジー カンパニー，リミテッド Pyrimidine compounds
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
JP2007291087A (en) 2006-03-29 2007-11-08 Taisho Pharmaceut Co Ltd Pyridine derivatives and therapies associated with their use
UA95644C2 (en) 2006-07-25 2011-08-25 Сефалон, Инк. Pyridizinone derivative, pharmaceutical composition and treatment method
US20080255155A1 (en) 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
WO2008061796A2 (en) 2006-11-24 2008-05-29 Ac Immune Sa Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
KR101442288B1 (en) 2006-12-13 2014-09-19 지보당 네덜란드 서비시즈 비.브이. Flavor control derivatives of carboxylic acids and purines, pyrimidines, nucleosides or nucleotides
EP2205639B1 (en) * 2007-10-26 2015-12-23 Merck Sharp & Dohme Corp. Anti-pcsk9 and methods for treating lipid and cholesterol disorders
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
MX2012001504A (en) 2009-08-05 2012-06-01 Versitech Ltd Antiviral compounds and methods of making and using there of cross reference to related applications.
AU2011253058A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
CN102933559B (en) 2010-06-04 2016-01-27 兴和株式会社 Optically active dibenzylamine derivative and its preparation method
JP5925771B2 (en) 2010-06-24 2016-05-25 トラスティーズ オブ タフツ カレッジ Niacin mimics and methods of use
WO2011163612A1 (en) 2010-06-24 2011-12-29 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
EP2592933B1 (en) 2010-07-16 2017-04-05 Anderson Gaweco Mif inhibitors and their uses
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
JP2014506878A (en) 2011-01-28 2014-03-20 ノバルティス アーゲー Substituted bi-heteroaryl compounds as CDK9 inhibitors and their use
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
WO2012162635A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
US8815909B2 (en) 2011-07-18 2014-08-26 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
JP5741850B2 (en) 2011-09-13 2015-07-01 コニカミノルタ株式会社 Optical film, polarizing plate including the same, and liquid crystal display device
US10028926B2 (en) 2012-01-06 2018-07-24 Gemphire Therapeutics Inc. Methods of reducing risk of cardiovascular disease
TW201348231A (en) 2012-02-29 2013-12-01 Amgen Inc Heterobicyclic compounds
WO2013134047A2 (en) 2012-03-07 2013-09-12 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
JPWO2013137371A1 (en) 2012-03-15 2015-08-03 興和株式会社 Novel pyrimidine compounds and pharmaceuticals containing them
WO2013158939A1 (en) 2012-04-18 2013-10-24 Hemoshear, Llc In vitro model for pathological or physiologic conditions
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CA2874244A1 (en) 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
AR092924A1 (en) 2012-10-09 2015-05-06 Sanofi Sa PIRROLIDINONE DERIVATIVES AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
TWI644899B (en) 2013-02-04 2018-12-21 健生藥品公司 Flap modulators
AU2014211727B2 (en) 2013-02-04 2018-07-26 Prexton Therapeutics Sa Positive allosteric modulators of mGluR3
SI3527563T1 (en) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
MX2015014666A (en) 2013-04-17 2016-03-01 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases.
TWI682780B (en) 2013-05-30 2020-01-21 美商再生元醫藥公司 Use of a pharmaceutical composition for the manufacture of a medicament for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
TW202021614A (en) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
WO2014201173A1 (en) 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
AR092240A1 (en) 2013-08-26 2015-04-08 Sunshine Lake Pharma Co Ltd NITROGEN HETEROCICLIC DERIVATIVES AND ITS APPLICATION IN PHARMACOS
CN105658232A (en) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 Methods of using interleukin-10 for treating diseases and disorders
KR20220048051A (en) 2013-10-11 2022-04-19 사노피 바이오테크놀로지 Use of a pcsk9 inhibitor to treat hyperlipidemia
CN104558685B (en) 2013-10-24 2017-09-29 中国石油化工股份有限公司 A kind of phosphorus nitrogen expansion type combustion inhibitor and its synthetic method
JP2017019724A (en) 2013-10-25 2017-01-26 第一三共株式会社 Substituted pyridine compounds and other pharmaceutical combinations
EP3080148A2 (en) 2013-12-11 2016-10-19 Glycotope GmbH Glycosylated glycophorin peptides
WO2015086732A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080155A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
LT3119757T (en) 2014-03-17 2018-07-10 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
AR099936A1 (en) 2014-04-04 2016-08-31 Sanofi Sa CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
AR099937A1 (en) 2014-04-04 2016-08-31 Sanofi Sa ISOINDOLINONE COMPOUNDS AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
EP3126346B1 (en) 2014-04-04 2018-07-11 Sanofi Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
EP3148537B1 (en) 2014-05-30 2018-09-26 Université Paris Descartes Cyclic compounds having a 1,3 diamino-functionality for use in the treatment of hiv infection
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI677489B (en) 2014-06-20 2019-11-21 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
RU2723018C2 (en) 2014-07-16 2020-06-08 Санофи Байотекнолоджи Methods of treating patients with a high risk of cardiovascular diseases having hypercholesterolemia
ES2826443T3 (en) 2014-09-25 2021-05-18 Araxes Pharma Llc KRAS G12C Mutant Protein Inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
BR112017015273A2 (en) 2015-01-20 2018-01-09 Merial Inc. anthelmintic compounds and compositions and method of uses thereof
WO2016127102A2 (en) 2015-02-06 2016-08-11 Ernesto Abel-Santos Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
AR103954A1 (en) 2015-03-18 2017-06-14 Zealand Pharma As AMILINE ANALOGS
EP3973958A3 (en) 2015-03-20 2022-06-22 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AU2016348638A1 (en) 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease
TW201731867A (en) 2015-12-02 2017-09-16 賽諾菲公司 FGF21 variant
IL303850A (en) 2015-12-11 2023-08-01 Univ Pennsylvania Gene therapy for the treatment of familial hypercholesterolemia
WO2017125506A1 (en) 2016-01-20 2017-07-27 Janssen Sciences Ireland Uc Aryl substituted pyrimidines for use in influenza virus infection
CN108697677A (en) 2016-02-26 2018-10-23 燿石治疗公司 Treatment to the homozygous familial hypercholesterolemiapatients patients for just receiving Comprehensive Therapy for Correcting Lipidemia
CN109152784B (en) 2016-03-16 2021-12-28 库拉肿瘤学公司 Substituted MENIN-MLL inhibitors and methods of use
JP2019513802A (en) 2016-04-14 2019-05-30 ルシー マイケル COMBINATION COMPOSITION AND METHOD OF USE THEREOF
TW201808888A (en) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 Modulators of the integrated stress pathway
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
JP2019532049A (en) 2016-09-15 2019-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Modulation method of PCSK9 and LDLR through DRP1 inhibition
LT3529360T (en) 2016-10-18 2024-07-25 Novartis Ag Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
SG11201903945XA (en) 2016-11-10 2019-05-30 Csl Ltd Reconstituted high density lipoprotein treatment of myocardial infarction
JOP20190112A1 (en) 2016-11-14 2019-05-14 Amgen Inc Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CN110267964B (en) 2016-12-13 2022-05-03 百时美施贵宝公司 Substituted heteroarylphosphine oxide compounds as IL-12, IL-23 and/or IFNα response modulators
EP3579782B1 (en) 2017-02-08 2024-05-01 Brooke Schumm Intra-operative radiation therapy capsule with cylindrical shell radiation containment shutter system
CN110637027B (en) 2017-02-08 2024-08-30 百时美施贵宝公司 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof
AR110988A1 (en) 2017-02-21 2019-05-22 Sanofi Sa AZETIDINE COMPOUNDS AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
WO2018165718A1 (en) 2017-03-17 2018-09-20 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of pcsk9
CN110691779B (en) 2017-03-24 2023-10-10 库拉肿瘤学公司 Approaches to Treating Hematologic Malignancies and Ewing's Sarcoma
JP2020517242A (en) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー Anti-ApoC3 antibody and method of using the same
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating S1P1 activity and methods of using them
WO2019001379A1 (en) 2017-06-26 2019-01-03 深圳市塔吉瑞生物医药有限公司 Indazole compound for use in inhibiting kinase activity, composition and application thereof
CN109384712B (en) 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 NK1 receptor targeting antagonist and application thereof in treatment of nausea and vomiting caused by chemotherapy
WO2019079701A1 (en) 2017-10-20 2019-04-25 Dana-Farber Cancer Institute, Inc. Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
EP3687538B1 (en) 2017-10-30 2024-04-17 Montreal Heart Institute Methods of treating elevated plasma cholesterol
KR20200074975A (en) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. Anti-ApoC3 antibodies and methods of use
UY37957A (en) 2017-11-02 2019-05-31 Abbvie Inc INTEGRATED STRESS ROAD MODULATORS
MX2020005210A (en) 2017-11-21 2020-08-20 Bristol Myers Squibb Co Sulfone pyridine alkyl amide-substituted heteroaryl compounds.
WO2019111225A1 (en) 2017-12-08 2019-06-13 Avaliv Therapeutics Compounds and methods for the treatment of non‑alcoholic steatohepatitis
WO2019126071A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
CA3088788A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US11513131B2 (en) 2018-01-22 2022-11-29 Global Genomics Group, LLC Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof
JP2021512051A (en) 2018-01-23 2021-05-13 ギラ セラピューティクス インコーポレイテッドＧｉｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Peptide YY Pharmaceutical Preparations, Compositions, and Methods
JP2021517141A (en) 2018-03-09 2021-07-15 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Combination therapy for cardiovascular disease
EP3768667B1 (en) 2018-03-22 2023-04-12 Bristol-Myers Squibb Company Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses
CN110384801B (en) 2018-04-20 2021-09-14 中国科学院上海药物研究所 Application of miRNA552 cluster microRNA in treatment of LDLC related metabolic diseases
ES2969982T3 (en) 2018-04-24 2024-05-23 Vertex Pharma Pteridinone compounds and uses thereof
US20190374526A1 (en) 2018-06-06 2019-12-12 Merck Sharp & Dohme Corp. Substituted Heterocyclic Compounds as Inhibitors of PRDM9
US11442072B2 (en) 2018-07-10 2022-09-13 Jenny and Antti Wihuri Foundation Method for measuring LDL aggregation
CR20210110A (en) 2018-08-31 2021-05-13 Pfizer Combinations for treatment of nash/nafld and related diseases
WO2020070678A2 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
CN113286885A (en) 2018-11-09 2021-08-20 诺华股份有限公司 Methods of reducing the risk of cardiovascular events with conjugated antisense compounds targeting apo (a)
CA3122035A1 (en) 2018-12-06 2020-06-11 Zora Biosciences Oy Biomarkers for cardiovascular events
AU2020209216A1 (en) * 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
SG11202107614PA (en) * 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN111484480B (en) 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 A polycyclic derivative inhibitor, its preparation method and application
WO2020160518A1 (en) 2019-02-01 2020-08-06 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
WO2020214753A1 (en) 2019-04-17 2020-10-22 Ngm Biopharmaceuticals, Inc. Combination therapy for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2020234726A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
JP2023506732A (en) 2019-12-10 2023-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Use of PCSK9 inhibitors to treat homozygous familial hypercholesterolemia
WO2021209808A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
CN113713107B (en) 2020-05-26 2022-09-23 中国科学院上海药物研究所 Application of miRNA552 cluster microRNA in treatment of glycolipid metabolic disease
CA3179316A1 (en) 2020-05-29 2021-12-02 Andrew W. HAMER Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders
TWI897977B (en) 2020-06-10 2025-09-21 荷蘭商菲林公司 Pharmaceutical compound for the treatment of atherosclerotic cardiovascular disease
WO2022028317A1 (en) 2020-08-05 2022-02-10 Rezubio Pharmaceuticals Co., Ltd Antidiabetic compounds and compositions
WO2022029334A1 (en) 2020-08-07 2022-02-10 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
WO2022040371A1 (en) 2020-08-19 2022-02-24 Biogen Ma Inc. Methods for treating hypercholesterolemia
JP2023543409A (en) 2020-09-15 2023-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Use of LEPR agonists for pain
PL4232448T3 (en) 2020-10-20 2025-10-13 Halo Therapeutics Ltd Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor
WO2022098841A1 (en) 2020-11-05 2022-05-12 Amgen Inc. METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
US12419888B2 (en) 2020-12-11 2025-09-23 Institut De Cardiologie De Montreal Methods of treating elevated plasma cholesterol
WO2022123120A1 (en) 2020-12-11 2022-06-16 Helsingin Yliopisto Method for determining a likelihood of a subject to respond to lipid lowering therapy
PL4294257T3 (en) 2021-02-22 2026-02-09 Regeneron Pharmaceuticals, Inc. Method for diagnosing and treating partial lipodystrophy
WO2022182918A1 (en) 2021-02-25 2022-09-01 Icahn School Of Medicine At Mount Sinai Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease
EP4312978A2 (en) 2021-03-27 2024-02-07 TRX Biosciences Limited Compositions having improved bioavailability of therapeutics
AU2022299514A1 (en) 2021-06-24 2024-01-18 Sirnaomics, Inc. Products and compositions
EP4359441A1 (en) 2021-06-25 2024-05-01 Amgen Inc. Treatment of cardiovascular disease with trem-1 antigen binding proteins
WO2023285583A1 (en) 2021-07-14 2023-01-19 Eternygen Uk Ltd. 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives for use in the treatment of diseases responsive to citrate transporter modulation
WO2023052783A1 (en) 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
WO2023079294A1 (en) 2021-11-05 2023-05-11 Sitryx Therapeutics Limited Phthalazine derivatives as pyruvate kinase modulators
EP4446307A4 (en) 2021-11-12 2025-12-10 Shenzhen Jingtai Tech Co Ltd Derivative of asparagic acid and its use in the treatment of metabolic disorders such as liver fibrosis and non-alcoholic hepatitis
CN114277032A (en) 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 Low-density lipoprotein receptor gene mutant and application thereof
US20250223281A1 (en) 2022-01-14 2025-07-10 Rezubio Pharmaceuticals Co., Ltd Antidiabetic compounds and compositions
TW202345865A (en) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 Composition and method for inhibiting expression of protein LPA(Apo(a))
CN116617390A (en) 2022-02-11 2023-08-22 武汉大学 Use of ASGR1 inhibitors for promoting cholesterol efflux and for treating non-alcoholic fatty liver disease
US20250177377A1 (en) 2022-03-11 2025-06-05 University Of Florida Research Foundation, Incorporated Targeting ptchd1 and neuronal cholesterol to enhance safety of opioid analgesics
US20230338419A1 (en) 2022-03-21 2023-10-26 The Trustees Of The University Of Pennsylvania Methods and apparatus for diagnosis and detection of cardiac allograft vasculopathy
CN119161484A (en) 2022-04-25 2024-12-20 武汉大学 Anti-ASGR1 monoclonal antibody and its application
US20250295724A1 (en) 2022-05-13 2025-09-25 Zhejiang Yangshengtang Institute Of Natural Medication Co., Ltd. Composition of malus niedzwetzkyana dieck and prunus cerasifera ehrhart and use thereof in terms of resisting atherosclerosis
CN115581694A (en) 2022-11-10 2023-01-10 正大青春宝药业有限公司 Application of senkyunolide I in preparation of medicine for treating hyperlipidemia
CN117180404A (en) 2023-10-24 2023-12-08 清华大学 The use of cholesin in regulating cholesterol homeostasis
CN117482076A (en) 2023-11-24 2024-02-02 中国人民解放军陆军军医大学第二附属医院 Application of methionine compounds in the preparation of PCSK9 inhibitors

Also Published As

Publication number Publication date
US20200231584A1 (en) 2020-07-23
EP3911640A1 (en) 2021-11-24
AU2020209216A1 (en) 2021-08-26
MX2024009001A (en) 2024-07-31
US20230407285A1 (en) 2023-12-21
EP3911640A4 (en) 2022-10-26
AU2023201972B2 (en) 2025-02-13
AU2023201972C1 (en) 2025-10-23
KR20210116549A (en) 2021-09-27
SG11202107615TA (en) 2021-08-30
WO2020150474A1 (en) 2020-07-23
TW202042817A (en) 2020-12-01
AU2025202886A1 (en) 2025-05-15
MX2021008661A (en) 2021-08-19
US11603523B2 (en) 2023-03-14
JP2022518016A (en) 2022-03-11
US12584120B2 (en) 2026-03-24
IL284661A (en) 2021-08-31
AU2023201972A1 (en) 2023-05-04
CA3125767A1 (en) 2020-07-23
MA54758A (en) 2022-04-27
BR112021013924A2 (en) 2021-09-21
EA202191890A1 (en) 2022-02-03
JP2025106240A (en) 2025-07-15
KR20260035207A (en) 2026-03-12
CN113412258A (en) 2021-09-17

Similar Documents

Publication Publication Date Title
MX2024009001A (en) Pcsk9 inhibitors and methods of use thereof.
EP4069212A4 (en) INHIBITORS OF HIF-2ALPHA
PH12022551503A1 (en) Kras mutant protein inhibitors
IL284640A (en) PCSK9 inhibitors and methods of using them
IL286373B2 (en) Protein tyrosine phosphatase inhibitor compounds and uses thereof
DK3966207T3 (en) PHENYLAMINOPYRIMIDINAMIDE AUTOPHAGY INHIBITORS AND METHODS OF USING THEREOF
DK3966206T3 (en) HETEROARYLAMINOPYRIMIDINAMIDE AUTOPHAGY INHIBITORS AND METHODS OF USING THEREOF
IL308476A (en) Inhibitors of the menin-mll interaction
ZA202109737B (en) Compound used as kinase inhibitor and application thereof
EP4028013A4 (en) Inhibitors of sarm1
ZA202202245B (en) Quinoline derivatives as protein kinase inhibitors
EP3749365A4 (en) Peptidyl inhibitors of calcineurin-nfat interaction
IL291158A (en) Iraq inhibitor and the method of preparation therefor and its use
EP4240363A4 (en) 7-PHENYL-SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1
EA201790484A1 (en) Derivatives of tetrahydroquinoline as bromodomain inhibitors
EP4333821A4 (en) INHIBITORS OF SARS-COV-2
EA202192575A1 (en) DBAIT COMPOUNDS IN COMBINATION WITH KINASE INHIBITORS FOR CANCER TREATMENT
EA201892051A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MALIGNANT NON-FORMATION
IL281451A (en) Uses of Plasminogen Activator Inhibitor 1 (PAI-1) Inhibitors
EP4240361A4 (en) 7-AZOLE-SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1
IL281450A (en) Plasminogen activator inhibitor 1 (PAI-1) inhibitors and uses thereof
EP4384164A4 (en) INHIBITORS OF HYPOXI-INDUCIBLE FACTORS
EP4069229A4 (en) SOLID STATE FORMS OF HDAC INHIBITOR
JOP20230205A1 (en) Vmat2 inhibitors and methods of use
IL291368A (en) Inhibitor of metadherin expression